Surgery and chemotherapy for intrahepatic cholangiocarcinoma

Table 1 Recent reported series of hepatectomy for intrahepatic cholangiocarcinoma

			Survival rate (%) and MST
Authors	Year	No	1-yr	3-yr	5-yr	MST (mo)	Significant prognostic factors for survival
Okabayashi	2001	60	68	35	29	19.6	Number of nodules, lymph-node involvement, vascular invasion, symptomatic tumor
Chen	1999	48	35.5	20.5	16.51
			27.2	8.8	7.82
DeOliveira	2007	44			40	28	Surgical margin
Palik	2008	97	74.9	51.8	31.1		Number of nodules, surgical margin
Inoue	2000	52	63	36	36	18	Surgical margin, lymph-node involvements, vascular invasion
Valverde	1999	30	86	22	22	28	Number of nodules, lymph-node involvements
Madariaga	1998	34	67	40	35	19	Number of nodules, surgical margin
Shimada	2007	94	69.5	35.5	31.1	24	Number of nodules, surgical margin, lymph-node involvements
Weber	2001	33		55	31	37.4	Vascular invasion

¹Data from intrahepatic cholangiocarcinoma patients with hepatolithiasis;

²Data from intrahepatic cholangiocarcinoma patients without hepatolithiasis; MST: Median survival time.

Table 2 Recent phase II studies of chemotherapy for biliary tract carcinoma

Agents	n	RR (%)	PFS (M)	MST (M)	Authors	Year
Gemcitabine
1000mg/m2, 30-min infusion	25	36		6.9	Gallardo	2001
	24	12.5	2.5	7.2	Lin	2003
	40	17.5	2.6	7.6	Okusaka	2006
Fluoropyrimidine
Capecitabine	26	19		8.1	Patt	2004
S-1	19	21	3.7	8.3	Ueno	2004
S-1	40	32.5	3.7	9.4	Furuse	2008
Others
Docetaxel	24	20	6.0	8.0	Papakostas	2001
CPT-11	36	8	2.7	6.1	Alberts	2002
Erlotinib	42	8	2.6	7.5	Philip	2006
Gemcitabine + fluoropyrimidine
Gem/5FU	27	33	3.7	5.3	Knox	2004
Gem/5FU/LV	30	20	3.7	4.7	Hsu	2004
Gem/5FU/LV	42	12	4.6	9.7	Alberts	2005
Gem/capecitabine	45	31	7.0	14.0	Knox	2005
Gem/capecitabine	45	32	6.0	14.0	Cho	2005
Gemcitabine + platinum
Gem/cisplatin	30	37	4.1	4.6	Doval	2004
Gem/cisplatin	40	28	4.7	8.4	Thongprasert	2005
Gem/cisplatin	29	35	3.0	11.0	Kim	2006
Gem/cisplatin	27	33	5.6	10.0	Park	2006
Gem/oxaliplatin	33	33	5.7	15.4	Andre	2004
Gem/oxaliplatin/bevacizumab	26	29	7.6		Clark	2007
Fluoropyrimidine + platinum
Capecitabine/oxaliplatin	65	20	6.5	12.8	Nehls	2006
S-1/cisplatin	51	30	4.8	8.7	Kim	2007

RR: Response rate; PFS: Median progression-free survival; ST: Median overall survival; FU: Fluorouracil.